Boehringer Ingelheim Fremont, Inc
6701 Kaiser Drive
About Boehringer Ingelheim Fremont, Inc
Boehringer Ingelheim Fremont is part of a global, privately held, family owned company founded in 1885. Boehringer Ingelheim Fremont is committed to researching, developing and manufacturing oncology and anti-inflamatory medicines. At Boehringer Ingelheim Fremont, more than 400 scientist and specialists come to work every day committed to making high quality medicine for patients.
Boehringer Ingelheim Fremont also offers tailor-made contract development and manufacturing services to the biopharmaceutical industry. Known as Boehringer Ingelheim BioXcellence™, this section of the company provides the entire production technology chain from DNA to fill and finish under one roof at facilities in Biberach (Germany), Fremont, CA (U.S.A.), Shanghai (China) and Vienna (Austria). Boehringer Ingelheim BioXcellence can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.
Boehringer Ingelheim’s goal is to provide value to patients and healthcare providers through innovation.
Boehringer Ingelheim, an industry leader in the production of biologics for more than 35 years, is developing biosimilars, a new type of biologic medicine.
880 articles with Boehringer Ingelheim Fremont, Inc
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease
Boehringer Ingelheim and Eli Lilly released data from their Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III trial in type 1 diabetes.
9/24/2018Here's a look at who's making moves in the biotech and pharma world this week.
Boehringer Ingelheim announced earlier this week that Christopher Corsico was leaving the company, effective December 31. Today it was announced that Corsico will join GSK to take on the new role of senior vice president of development.
9/13/2018Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
Job hunting can be a challenging time for people. Finding open positions that fit your skill set and then competing with other highly-qualified people can be bruising, especially if you’re already a bit damaged from a recent layoff.
In May the U.S. Food and Drug Administration approved Amgen’s preventative migraine treatment Aimovig. Amgen and its developmental partner Novartis, said the medication would be ready within one week for patients.
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has approved the Novartis CAR-T cell therapy, Kymriah® (tisagenlecleucel, formerly CTL019).
Calculus Capital, the award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments.
Boehringer Ingelheim Demonstrates Their Commitment to Site Relationships by Joining SCRS’ Global Impact Partner Program
Becoming a GIP demonstrates the company’s commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions.
Another potential treatment for Alzheimer's disease has been tossed into the rubbish bin.
Merial, Now Part of Boehringer Ingelheim, Grows Canine Vaccine Portfolio With Introduction of RECOMBITEK Oral Bordetella
RECOMBITEK vaccines are manufactured by Merial. Merial is now a part of Boehringer Ingelheim.
Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018.
Boehringer Ingelheim announced today that Paul Fonteyne, U.S. President and CEO will retire after 15 years of committed service on December 31, 2018.
As a PBM owned by 18 Blue Cross and Blue Shield plans, Prime is uniquely positioned to analyze both medical and pharmacy claims data to evaluate and manage total cost of care.
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
The study examined major bleeding and stroke rates in NVAF patients who had initiated treatment with Pradaxa compared to those treated with rivaroxaban or apixaban.
Boehringer Ingelheim Release: Respimat Inhaler Awarded Arthritis Foundation’s Ease of Use Commendation
Boehringer Ingelheim announced today that the Arthritis Foundation recognized Respimat with its Ease of Use Commendation.
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
Tislelizumab will be manufactured in Boehringer Ingelheim’s world-class biopharmaceutical manufacturing facility in Shanghai.
Boehringer Ingelheim Release: New Documentary Film Shines Light on Physical and Emotional Impact of COPD
The film was created by Emmy-nominated director Abbey LeVine in collaboration with Boehringer Ingelheim Pharmaceuticals.
The collaboration is part of Boehringer Ingelheim's RBB initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.